NCT05262426Completed
Developing mHealth to Promote PrEP Use Among Thai Young Vulnerable Adolescents and Emerging Adults
Optimizing an mHealth Intervention to Improve Uptake and Adherence of the HIV Pre-exposure Prophylaxis (PrEP) in Vulnerable Adolescents and Emerging Adults
Source: ClinicalTrials.gov · Last updated 8 Sept 2026
Brief summary (registry, in English)
The main aim of this study is to develop technology-based interventions to improve HIV pre-exposure prophylaxis (PrEP) uptake and adherence among Thai young transgender women.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 145 (actual)
- First submitted
- 7 Feb 2022
- Start date
- 27 Dec 2021
- Primary completion date
- 31 Jan 2026
- Lead sponsor
- University of Massachusetts, Worcester
- Diseases
- HIV
- NCT number
- NCT05262426
What you commit to
- Study type: Interventional
- Participants enrolled: 145
- From 27 Dec 2021 to the primary completion date, 31 Jan 2026
- 3 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Have a serious cognitive or psychiatric problem that would compromise ability to provide informed consent
- Have active suicidal ideation or major mental illness (e.g., untreated psychosis or mania) at the time of interview (patients will be referred for treatment)
- Have a serious cognitive or psychiatric problem that would compromise ability to provide informed consent
- Have active suicidal ideation or major mental illness (e.g., untreated psychosis or mania) at the time of interview (patients will be referred for treatment)
- Currently enrolled in another HIV intervention study
Lab values
- Laboratory or clinical findings that would preclude PrEP initiation (e.g., decreased creatinine clearance)
- Healthcare providers
- Laboratory or clinical findings that would preclude PrEP initiation (e.g., decreased creatinine clearance)
Other
- None
- Aim 2:
Who the study is looking for
- Age 16-29 years old
- Male sex at birth
- Self-identifies as woman or transgender women or culturally identifies with the female spectrum
- Confirmed HIV-negative status
- Self-reported recent history of condomless sex in the past 6 months
- Able to understand, read and speak Thai
- Either having not started PrEP (Group 1: PrEP naive), currently on PrEP but not adherent to PrEP (taking ≤3 pills/week) in the past month (Group 2: PrEP users) or currently on PrEP with good adherence (Group 3: PrEP users with good adherence).
- Have at least 1-year experience working with HIV-negative transgender women, including providing PrEP prescription and counseling
- Age 16-29 years old
- Male sex at birth
- Self-identifies as woman or transgender women or culturally identifies with the female spectrum
- Confirmed HIV-negative status
- Self-reported recent history of condomless sex in the past 6 months
- Able to understand, read and speak Thai
- Either having not started PrEP (Group 1: PrEP naive), currently on PrEP but not adherent to PrEP (taking ≤3 pills/week) in the past month (Group 2: PrEP users).
Criteria the registry did not label
- Aim 1:
- Transgender women participants
Age in the registry: 16 years to 29 years · Sex: Male · Accepts healthy volunteers
Sites (3)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Institute of HIV Research and Innovation Coordinator of this site? Confirm its status | Bangkok | Thailand | Unknown status |
| SWING Foundation Coordinator of this site? Confirm its status | Bangkok | Thailand | Unknown status |
| Rainbow Sky Association of Thailand Coordinator of this site? Confirm its status | Bangkok | Thailand | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.